IRRITABLE BOWEL SYNDROME: THE ROLE OF GUT MICROBIOTA IN ETIOLOGY AND TREATMENT. A LITERATURE REVIEW

Magdalena Cieślik-Porębska; Agata Cieślik

doi:10.31435/ijitss.1(49).2026.4612

Magdalena Cieślik-Porębska Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland https://orcid.org/0009-0002-2226-4317
Agata Cieślik Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland https://orcid.org/0009-0003-5496-9378

DOI: https://doi.org/10.31435/ijitss.1(49).2026.4612

Keywords: Gut Dysbiosis, Irritable Bowel Syndrome, Low FODMAP Diet, Gut Probiotics, Intestinal Microbiota Transplantation

Abstract

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder. Its etiology is thought to involve many factors. Recent reports suggest that gut microbiota disorders may play an important role in the pathophysiology of IBS. This opens the door to new treatment therapies.

Aim: The aim of this article is to review the latest research on the impact of changes in the gut microbiota on IBS, as well as methods of therapy that influence the modulation of the gut microbiota.

Material and methods: A literature review was conducted using the PubMed and Google Scholar databases. The focus was on studies published between 2015 and 2025.

Results: Changes in the gut microbiota play a significant role in IBS. However, there is still much uncertainty surrounding the exact pathomechanisms underlying this process. The low-FODMAP diet alleviates symptoms and causes changes in microbiota. Probiotics show moderate effectiveness, while the results of fecal microbiota transplantation are often inconclusive.

Conclusions: Further research is needed to determine the exact impact of gut microbiota on IBS. The low-FODMAP diet, probiotics, and fecal microbiota transplantation offer promising but inconclusive treatment results. Further standardized studies are needed to determine the best therapeutic strategies.

References

Ait-Belgnaoui, A., Colom, A., Braniste, V., Ramalho, L., Marrot, A., Cartier, C., Houdeau, E., Theodorou, V., & Tompkins, T. (2014). Probiotic gut effect prevents the chronic psychological stress-induced brain activity abnormality in mice. Neurogastroenterology and Motility, 26(4), 510–520. https://doi.org/10.1111/nmo.12295

Altobelli, E., Del Negro, V., Angeletti, P. M., & Latella, G. (2017). Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis. Nutrients, 9(9), 940. https://doi.org/10.3390/NU9090940

Aziz, M. N. M., Kumar, J., Nawawi, K. N. M., Ali, R. A. R., & Mokhtar, N. M. (2021). Irritable Bowel Syndrome, Depression, and Neurodegeneration: A Bidirectional Communication from Gut to Brain. Nutrients, 13(9), 3061. https://doi.org/10.3390/NU13093061

Barrett, J. S., & Gibson, P. R. (2012). Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Therapeutic Advances in Gastroenterology, 5(4), 261. https://doi.org/10.1177/1756283X11436241

Baunwall, S. M. D., Lee, M. M., Eriksen, M. K., Mullish, B. H., Marchesi, J. R., Dahlerup, J. F., & Hvas, C. L. (2020). Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine, 29–30, 100642. https://doi.org/10.1016/J.ECLINM.2020.100642

Bednarska, O., Walter, S. A., Casado-Bedmar, M., Ström, M., Salvo-Romero, E., Vicario, M., Mayer, E. A., & Keita, Å. V. (2017). Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome. Gastroenterology, 153(4), 948. https://doi.org/10.1053/J.GASTRO.2017.06.051

Bertin, L., Zanconato, M., Crepaldi, M., Marasco, G., Cremon, C., Barbara, G., Barberio, B., Zingone, F., & Savarino, E. V. (2024). The Role of the FODMAP Diet in IBS. Nutrients, 16(3), 370. https://doi.org/10.3390/NU16030370

Bhattarai, Y., Muniz Pedrogo, D. A., & Kashyap, P. C. (2017). Irritable bowel syndrome: a gut microbiota-related disorder? Https://Doi.Org/10.1152/Ajpgi.00338.2016, 312(1), G52–G62. https://doi.org/10.1152/AJPGI.00338.2016

Carabotti, M., Scirocco, A., Maselli, M. A., & Severi, C. (2015). The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology, 28(2), 203. https://pmc.ncbi.nlm.nih.gov/articles/PMC4367209/

Casado-Bedmar, M., & Keita, Å. V. (2020). Potential neuro-immune therapeutic targets in irritable bowel syndrome. Therapeutic Advances in Gastroenterology, 13, 1756284820910630. https://doi.org/10.1177/1756284820910630

Chen, Y., Feng, S., Li, Y., Zhang, C., Chao, G., & Zhang, S. (2024). Gut microbiota and intestinal immunity—A crosstalk in irritable bowel syndrome. Immunology, 172(1), 1–20. https://doi.org/10.1111/imm.13749

Chen, Y., Zhou, J., & Wang, L. (2021). Role and Mechanism of Gut Microbiota in Human Disease. Frontiers in Cellular and Infection Microbiology, 11, 625913. https://doi.org/10.3389/fcimb.2021.625913

Chlebicz-Wójcik, A., & Śliżewska, K. (2021). Probiotics, Prebiotics, and Synbiotics in the Irritable Bowel Syndrome Treatment: A Review. Biomolecules, 11(8), 1154. https://doi.org/10.3390/BIOM11081154

Dai, C., Huang, Y. H., & Jiang, M. (2024). Fecal microbiota transplantation for irritable bowel syndrome: Current evidence and perspectives. World Journal of Gastroenterology, 30(16), 2179. https://doi.org/10.3748/WJG.V30.I16.2179

Dale, H. F., Rasmussen, S. H., Asiller, Ö. Ö., & Lied, G. A. (2019). Probiotics in Irritable Bowel Syndrome: An Up-to-Date Systematic Review. Nutrients, 11(9), 2048. https://doi.org/10.3390/NU11092048

Dudík, B., Kiňová Sepová, H., Bilka, F., Pašková, Ľ., & Bilková, A. (2020). Mucin pre-cultivated Lactobacillus reuteri E shows enhanced adhesion and increases mucin expression in HT-29 cells. Antonie van Leeuwenhoek 2020 113:8, 113(8), 1191–1200. https://doi.org/10.1007/S10482-020-01426-1

Edogawa, S., Edwinson, A. L., Peters, S. A., Chikkamenahalli, L. L., Sundt, W., Graves, S., Gurunathan, S. V., Breen-Lyles, M., Johnson, S., Dyer, R., Graham, R., Chen, J., Kashyap, P., Farrugia, G., & Grover, M. (2019). Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in irritable bowel syndrome. Gut, 69(1), 62. https://doi.org/10.1136/GUTJNL-2018-317416

El-Salhy, M., Casen, C., Valeur, J., Hausken, T., & Hatlebakk, J. G. (2021). Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. World Journal of Gastroenterology, 27(18), 2219. https://doi.org/10.3748/WJG.V27.I18.2219

El-Salhy, M., & Gundersen, D. (2015). Diet in irritable bowel syndrome. Nutrition Journal, 14(1), 36. https://doi.org/10.1186/S12937-015-0022-3

El-Salhy, M., Hatlebakk, J. G., Gilja, O. H., Bråthen Kristoffersen, A., & Hausken, T. (2019). Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut, 69(5), 859. https://doi.org/10.1136/GUTJNL-2019-319630

El-Salhy, M., Hatlebakk, J. G., & Hausken, T. (2020). Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS). Neuropeptides, 79, 101973. https://doi.org/10.1016/J.NPEP.2019.101973

El-Salhy, M., Patcharatrakul, T., & Gonlachanvit, S. (2021). Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21st century. World Journal of Gastroenterology, 27(22), 2921. https://doi.org/10.3748/WJG.V27.I22.2921

El-Salhy, M., Valeur, J., Hausken, T., & Gunnar Hatlebakk, J. (2020). Changes in fecal short‐chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome. Neurogastroenterology and Motility, 33(2), e13983. https://doi.org/10.1111/NMO.13983

Giorgetti, G. M., Brandimarte, G., Fabiocchi, F., Ricci, S., Flamini, P., Sandri, G., Trotta, M. C., Elisei, W., Penna, A., Lecca, P. G., Picchio, M., & Tursi, A. (2015). Interactions between Innate Immunity, Microbiota, and Probiotics. Journal of Immunology Research, 2015, 501361. https://doi.org/10.1155/2015/501361

González-Rodríguez, I., Sánchez, B., Ruiz, L., Turroni, F., Ventura, M., Ruas-Madiedo, P., Gueimonde, M., & Margolles, A. (2012). Role of Extracellular Transaldolase from Bifidobacterium bifidum in Mucin Adhesion and Aggregation. Applied and Environmental Microbiology, 78(11), 3992. https://doi.org/10.1128/AEM.08024-11

Halkjær, S. I., Christensen, A. H., Lo, B. Z. S., Browne, P. D., Günther, S., Hansen, L. H., & Petersen, A. M. (2018). Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut, 67(12), 2107–2115. https://doi.org/10.1136/GUTJNL-2018-316434

Halkjær, S. I., Lo, B., Cold, F., Christensen, A. H., Holster, S., König, J., Brummer, R. J., Aroniadis, O. C., Lahtinen, P., Holvoet, T., Gluud, L. L., & Petersen, A. M. (2023). Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. World Journal of Gastroenterology, 29(20), 3185. https://doi.org/10.3748/WJG.V29.I20.3185

Halmos, E. P., Christophersen, C. T., Bird, A. R., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2015). Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut, 64(1), 93–100. https://doi.org/10.1136/GUTJNL-2014-307264

Hanning, N., Edwinson, A. L., Ceuleers, H., Peters, S. A., De Man, J. G., Hassett, L. C., De Winter, B. Y., & Grover, M. (2021). Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therapeutic Advances in Gastroenterology, 14, 1756284821993586. https://doi.org/10.1177/1756284821993586

Herndon, C. C., Wang, Y. P., & Lu, C. L. (2019). Targeting the gut microbiota for the treatment of irritable bowel syndrome. The Kaohsiung Journal of Medical Sciences, 36(3), 160. https://doi.org/10.1002/KJM2.12154

Hillestad, E. M. R., van der Meeren, A., Nagaraja, B. H., Bjørsvik, B. R., Haleem, N., Benitez-Paez, A., Sanz, Y., Hausken, T., Lied, G. A., Lundervold, A., & Berentsen, B. (2022). Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome. World Journal of Gastroenterology, 28(4), 412. https://doi.org/10.3748/WJG.V28.I4.412

Holster, S., Lindqvist, C. M., Repsilber, D., Salonen, A., De Vos, W. M., Konig, J., & Brummer, R. J. (2019). The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study. Clinical and Translational Gastroenterology, 10(4), e00034. https://doi.org/10.14309/CTG.0000000000000034

Horvat, I. B., Gobin, I., Kresović, A., & Hauser, G. (2021). How can probiotic improve irritable bowel syndrome symptoms? World Journal of Gastrointestinal Surgery, 13(9), 923. https://doi.org/10.4240/WJGS.V13.I9.923

Hou, S., Yu, J., Li, Y., Zhao, D., & Zhang, Z. (2025). Advances in Fecal Microbiota Transplantation for Gut Dysbiosis‐Related Diseases. Advanced Science, 12(13), 2413197. https://doi.org/10.1002/ADVS.202413197

Jalanka, J., Salonen, A., Fuentes, S., & de Vos, W. M. (2015). Microbial signatures in post-infectious irritable bowel syndrome – toward patient stratification for improved diagnostics and treatment. Gut Microbes, 6(6), 364. https://doi.org/10.1080/19490976.2015.1096486

Jayasinghe, M., Karunanayake, V., Mohtashim, A., Caldera, D., Mendis, P., Prathiraja, O., Rashidi, F., & Damianos, J. A. (2024). The Role of Diet in the Management of Irritable Bowel Syndrome: A Comprehensive Review. Cureus, 16(2), e54244. https://doi.org/10.7759/CUREUS.54244

Mazzawi, T., Gundersen, D., Hausken, T., & El-Salhy, M. (2015). Increased Chromogranin A Cell Density in the Large Intestine of Patients with Irritable Bowel Syndrome after Receiving Dietary Guidance. Gastroenterology Research and Practice, 2015, 823897. https://doi.org/10.1155/2015/823897

Mazzawi, T., Hausken, T., Gundersen, D., & El-Salhy, M. (2014). Effect of dietary management on the gastric endocrine cells in patients with irritable bowel syndrome. European Journal of Clinical Nutrition, 69(4), 519. https://doi.org/10.1038/EJCN.2014.151

Mishima, Y., & Ishihara, S. (2020). Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome. International Journal of Molecular Sciences, 21(22), 8664. https://doi.org/10.3390/IJMS21228664

Nozu, T., Miyagishi, S., Nozu, R., Takakusaki, K., & Okumura, T. (2019). Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome. Scientific Reports, 9(1), 19603. https://doi.org/10.1038/S41598-019-56132-4

Osadchiy, V., Martin, C. R., & Mayer, E. A. (2018). The Gut–Brain Axis and the Microbiome: Mechanisms and Clinical Implications. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, 17(2), 322. https://doi.org/10.1016/J.CGH.2018.10.002

Plaza-Diaz, J., Ruiz-Ojeda, F. J., Gil-Campos, M., & Gil, A. (2019). Mechanisms of Action of Probiotics. Advances in Nutrition, 10(Suppl 1), S49. https://doi.org/10.1093/advances/nmy063

Pozuelo, M., Panda, S., Santiago, A., Mendez, S., Accarino, A., Santos, J., Guarner, F., Azpiroz, F., & Manichanh, C. (2015). Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Scientific Reports, 5, 12693. https://doi.org/10.1038/SREP12693

Raskov, H., Burcharth, J., Pommergaard, H. C., & Rosenberg, J. (2016). Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes, 7(5), 365–383. https://doi.org/10.1080/19490976.2016.1218585

Reddel, S., Putignani, L., & Del Chierico, F. (2019). The Impact of Low-FODMAPs, Gluten-Free, and Ketogenic Diets on Gut Microbiota Modulation in Pathological Conditions. Nutrients, 11(2), 373. https://doi.org/10.3390/NU11020373

Rodiño, B. K., María, J., Carmen, V., Roberto, A.-C., Santos, P.-G. J., Rodiño-Janeiro, B. K., Alonso-Cotoner, C., Santos, Á. J., Santos, J., Vicario, M., Alonso-Cotoner, Á. C., & Pascua-García, R. (2018). A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Advances in Therapy 2018 35:3, 35(3), 289–310. https://doi.org/10.1007/S12325-018-0673-5

Schwille-Kiuntke, J., Mazurak, N., & Enck, P. (2015). Systematic review with meta-analysis: Post-infectious irritable bowel syndrome after travellers’ diarrhoea. Alimentary Pharmacology and Therapeutics, 41(11), 1029–1037. https://doi.org/10.1111/apt.13199

Sciavilla, P., Strati, F., Di Paola, M., Modesto, M., Vitali, F., Cavalieri, D., Prati, G. M., Di Vito, M., Aragona, G., De Filippo, C., & Mattarelli, P. (2021). Gut microbiota profiles and characterization of cultivable fungal isolates in IBS patients. Applied Microbiology and Biotechnology, 105(8), 3277. https://doi.org/10.1007/S00253-021-11264-4

Shukla, R., Ghoshal, U., Ranjan, P., & Ghoshal, U. C. (2018). Expression of Toll-like Receptors, Pro-, and Anti-inflammatory Cytokines in Relation to Gut Microbiota in Irritable Bowel Syndrome: The Evidence for Its Micro-organic Basis. Journal of Neurogastroenterology and Motility, 24(4), 628. https://doi.org/10.5056/JNM18130

Simon, E., Călinoiu, L. F., Mitrea, L., & Vodnar, D. C. (2021). Probiotics, Prebiotics, and Synbiotics: Implications and Beneficial Effects against Irritable Bowel Syndrome. Nutrients, 13(6), 2112. https://doi.org/10.3390/NU13062112

Singh, P., Grabauskas, G., Zhou, S. Y., Gao, J., Zhang, Y., & Owyang, C. (2021). High FODMAP diet causes barrier loss via lipopolysaccharide-mediated mast cell activation. JCI Insight, 6(22), e146529. https://doi.org/10.1172/JCI.INSIGHT.146529

Singh, P., Tuck, C., Gibson, P. R., & Chey, W. D. (2022). The Role of Food in the Treatment of Bowel Disorders: Focus on Irritable Bowel Syndrome and Functional Constipation. The American Journal of Gastroenterology, 117(6), 947. https://doi.org/10.14309/AJG.0000000000001767

Singh, S. V., Ganguly, R., Jaiswal, K., Yadav, A. K., Kumar, R., & Pandey, A. K. (2023). Molecular signalling during cross talk between gut brain axis regulation and progression of irritable bowel syndrome: A comprehensive review. World Journal of Clinical Cases, 11(19), 4458. https://doi.org/10.12998/WJCC.V11.I19.4458

Spiller, R., Pélerin, F., Cayzeele Decherf, A., Maudet, C., Housez, B., Cazaubiel, M., & Jüsten, P. (2015). Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterology Journal, 4(3), 353. https://doi.org/10.1177/2050640615602571

Sun, Y. Y., Li, M., Li, Y. Y., Li, L. X., Zhai, W. Z., Wang, P., Yang, X. X., Gu, X., Song, L. J., Li, Z., Zuo, X. L., & Li, Y. Q. (2018). The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Scientific Reports, 8(1), 2964. https://doi.org/10.1038/S41598-018-21241-Z

Sundin, J., Aziz, I., Nordlander, S., Polster, A., Hu, Y. O. O., Hugerth, L. W., Pennhag, A. A. L., Engstrand, L., Törnblom, H., Simrén, M., & Öhman, L. (2020). Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome. Scientific Reports 2020 10:1, 10(1), 593-. https://doi.org/10.1038/s41598-020-57468-y

Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., & Sanders, M. E. (2020). The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nature Reviews. Gastroenterology & Hepatology, 17(11), 687. https://doi.org/10.1038/S41575-020-0344-2

Tap, J., Derrien, M., Törnblom, H., Brazeilles, R., Cools-Portier, S., Doré, J., Störsrud, S., Le Nevé, B., Öhman, L., & Simrén, M. (2017). Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. Gastroenterology, 152(1), 111-123.e8. https://doi.org/10.1053/j.gastro.2016.09.049

Umu, Ö. C. O., Rudi, K., & Diep, D. B. (2017). Modulation of the gut microbiota by prebiotic fibres and bacteriocins. Microbial Ecology in Health and Disease, 28(1), 1348886. https://doi.org/10.1080/16512235.2017.1348886

van Lanen, A. S., de Bree, A., & Greyling, A. (2021). Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. European Journal of Nutrition, 60(6), 3505. https://doi.org/10.1007/S00394-020-02473-0

Vandeputte, D., & Joossens, M. (2020). Effects of Low and High FODMAP Diets on Human Gastrointestinal Microbiota Composition in Adults with Intestinal Diseases: A Systematic Review. Microorganisms, 8(11), 1638. https://doi.org/10.3390/MICROORGANISMS8111638

Wang, H., Gao, K., Wen, K., Allen, I. C., Li, G., Zhang, W., Kocher, J., Yang, X., Giri-Rachman, E., Li, G. H., Clark-Deener, S., & Yuan, L. (2016). Lactobacillus rhamnosus GG modulates innate signaling pathway and cytokine responses to rotavirus vaccine in intestinal mononuclear cells of gnotobiotic pigs transplanted with human gut microbiota. BMC Microbiology, 16(1), 109. https://doi.org/10.1186/S12866-016-0727-2

Wang, S., Xu, M., Wang, W., Cao, X., Piao, M., Khan, S., Yan, F., Cao, H., & Wang, B. (2016). Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS ONE, 11(8), e0161174. https://doi.org/10.1371/JOURNAL.PONE.0161174

Wen, X., Wang, H. G., Zhang, M. N., Zhang, M. H., Wang, H., & Yang, X. Z. (2021). Fecal microbiota transplantation ameliorates experimental colitis via gut microbiota and T-cell modulation. World Journal of Gastroenterology, 27(21), 2834. https://doi.org/10.3748/WJG.V27.I21.2834

Yadav, M. K., Kumari, I., Singh, B., Sharma, K. K., & Tiwari, S. K. (2022). Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics. Applied Microbiology and Biotechnology, 106(2), 505. https://doi.org/10.1007/S00253-021-11646-8

Yoo, J. Y., Groer, M., Dutra, S. V. O., Sarkar, A., & McSkimming, D. I. (2020). Gut Microbiota and Immune System Interactions. Microorganisms 2020, Vol. 8, 8(10), 1–22. https://doi.org/10.3390/MICROORGANISMS8101587

Zhang, J., Song, L., Wang, Y., Liu, C., Zhang, L., Zhu, S., Liu, S., & Duan, L. (2018). Beneficial effect of butyrate‐producing Lachnospiraceae on stress‐induced visceral hypersensitivity in rats. Journal of Gastroenterology and Hepatology, 34(8), 1368. https://doi.org/10.1111/JGH.14536

Zhang, Y., Li, L., Guo, C., Mu, D., Feng, B., Zuo, X., & Li, Y. (2016). Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterology, 16(1), 62. https://doi.org/10.1186/S12876-016-0470-Z

Zhou, S. Y., Gillilland, M., Wu, X., Leelasinjaroen, P., Zhang, G., Zhou, H., Ye, B., Lu, Y., & Owyang, C. (2017). FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction. The Journal of Clinical Investigation, 128(1), 267. https://doi.org/10.1172/JCI92390